The emerging roles of long non-coding RNA (lncRNA) H19 in gynecologic cancers.
Biomarker
Gynecologic cancer
H19
LncRNAs
Tumorigenesis
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
02 Jan 2024
02 Jan 2024
Historique:
received:
29
06
2023
accepted:
12
12
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
epublish
Résumé
Long non-coding RNA (lncRNA) H19 has gained significant recognition as a pivotal contributor to the initiation and advancement of gynecologic cancers, encompassing ovarian, endometrial, cervical, and breast cancers. H19 exhibits a complex array of mechanisms, demonstrating dualistic effects on tumorigenesis as it can function as both an oncogene and a tumor suppressor, contingent upon the specific context and type of cancer being investigated. In ovarian cancer, H19 promotes tumor growth, metastasis, and chemoresistance through modulation of key signaling pathways and interaction with microRNAs. Conversely, in endometrial cancer, H19 acts as a tumor suppressor by inhibiting proliferation, inducing apoptosis, and regulating epithelial-mesenchymal transition. Additionally, H19 has been implicated in cervical and breast cancers, where it influences cell proliferation, invasion, and immune evasion. Moreover, H19 has potential as a diagnostic and prognostic biomarker for gynecologic cancers, with its expression levels correlating with clinical parameters and patient outcomes. Understanding the functional roles of H19 in gynecologic cancers is crucial for the development of targeted therapeutic strategies and personalized treatment approaches. Further investigation into the intricate molecular mechanisms underlying H19's involvement in gynecologic malignancies is warranted to fully unravel its therapeutic potential and clinical implications. This review aims to elucidate the functional roles of H19 in various gynecologic malignancies.
Identifiants
pubmed: 38166752
doi: 10.1186/s12885-023-11743-z
pii: 10.1186/s12885-023-11743-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4Informations de copyright
© 2023. The Author(s).
Références
Di Fiore R, Suleiman S, Calleja-Agius J. CD133 as biomarker and therapeutic target in gynecologic malignancies. Springer; 2023.
doi: 10.1007/16833_2023_139
Ledford LRC, Lockwood S. Scope and epidemiology of gynecologic cancers: an overview. Semin Oncol Nurs. 2019;35:147–50.
pubmed: 30902519
doi: 10.1016/j.soncn.2019.03.002
Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers. 2021;13:4287.
pubmed: 34503097
pmcid: 8428369
doi: 10.3390/cancers13174287
Sheikhnezhad L, Hassankhani H, Sawin EM, Sanaat Z, Sahebihagh MH. Intimate partner violence in women with breast and gynaecologic cancers: a systematic review. J Adv Nurs. 2023;79:1211–24.
pubmed: 35799466
doi: 10.1111/jan.15285
Keyvani V, Kheradmand N, Navaei ZN, Mollazadeh S, Esmaeili S-A. Epidemiological trends and risk factors of gynecological cancers: an update. Med Oncol. 2023;40:93.
pubmed: 36757546
doi: 10.1007/s12032-023-01957-3
Wu R, Wu C, Zhu B, Li J, Zhao W. Screening and validation of potential markers associated with uterine corpus endometrial carcinoma and polycystic ovary syndrome based on bioinformatics methods. Front Mol Biosci. 2023;10:1192313.
pubmed: 37363398
pmcid: 10288877
doi: 10.3389/fmolb.2023.1192313
Shetty C, Rizvi SMHA, Sharaf J, Williams K-AD, Tariq M, Acharekar MV, et al. Risk of gynecological cancers in women with polycystic ovary syndrome and the pathophysiology of association. Cureus. 2023;15
Jones ME, Schoemaker MJ, Wright LB, Ashworth A, Swerdlow AJ. Smoking and risk of breast cancer in the generations study cohort. Breast Cancer Res. 2017;19:1–14.
doi: 10.1186/s13058-017-0908-4
Koshiyama M. The effects of the dietary and nutrient intake on gynecologic cancers. In Healthcare MDPI. 2019;88
Liontos M, Fiste O, Zagouri F, Dimopoulos MA. Advances in Gynecological Cancers. Int J Mol Sci. 2022;23
Lother D, Robert M, Elwood E, Smith S, Tunariu N, Johnston SRD, et al. Imaging in metastatic breast cancer, CT, PET/CT, MRI, WB-DWI, CCA: review and new perspectives. Cancer Imaging. 2023;23:53.
pubmed: 37254225
pmcid: 10230813
doi: 10.1186/s40644-023-00557-8
Şahin F, Aydın E, Öcal EUB, Özdemir S, Kasapoğlu AM, Akbayır Ö. Evaluation of colposcopy and LEEP results performed in gynecology and gynecological oncology surgery services. Eur J Gynaecol Oncol. 2023;1:8.
Vitale SG, Buzzaccarini G, Riemma G, Pacheco LA, Sardo ADS, Carugno J, et al. Endometrial biopsy: indications, techniques and recommendations. An evidence-based guideline for clinical practice. Journal of gynecology obstetrics and human. Reproduction. 2023:102588.
Bilir E, Kahramanoğlu İ. The role of hysteroscopy in fertility preservation in endometrial cancer and atypical endometrial hyperplasia: a semi-systematic literature review. Arch Gynecol Obstet. 2023:1–14.
Lu Y, Chen J, Wei R, Lin W, Chen Y, Su Y, et al. Application of robotic surgery and traditional laparoscopic surgery in lymph node dissection for gynecological cancer: a meta-analysis. Oncol Lett. 2023;25:1–10.
doi: 10.3892/ol.2023.13761
Onuki M, Takahashi F, Iwata T, Nakazawa H, Yahata H, Kanao H, et al. Human papillomavirus vaccine impact on invasive cervical cancer in Japan: preliminary results from cancer statistics and the MINT study. Cancer Sci. 2023;114(11):4426–32.
pubmed: 37688310
pmcid: 10637081
doi: 10.1111/cas.15943
Kahn RM, Ahsan MD, Chapman-Davis E, Holcomb K, Nitecki R, Rauh-Hain JA, et al. Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome? Familial Cancer. 2023;22:127–33.
pubmed: 36207653
doi: 10.1007/s10689-022-00316-x
Melli B, Sileo FG, Palicelli A, Kuhn E, Nardi V, Mandato VD. Tumor-infiltrating lymphocytes (TILs) and gynecological cancers. Springer; 2023.
doi: 10.1007/16833_2023_161
Alur-Gupta S, Fruchtman H, Paroder V. Fertility-sparing options for cancer patients. Abdom Radiol. 2023;48:1618–28.
doi: 10.1007/s00261-023-03839-8
Terao Y. Cutting-edge treatment for gynecological malignancies. Juntendo Med J. 2023;69:86–91.
doi: 10.14789/jmj.JMJ22-0044-R
Lee J, Lin J-B, Weng C-S, Chen S-J, Chen T-C, Chen Y-J. Impact of reduced margin pelvic radiotherapy on gastrointestinal toxicity and outcome in gynecological cancer. Clin Transl Radiation Oncol. 2023;43:100671.
doi: 10.1016/j.ctro.2023.100671
Qin M, Zhang C, Li Y. Circular RNAs in gynecologic cancers: mechanisms and implications for chemotherapy resistance. Front Pharmacol. 2023;14:1194719.
pubmed: 37361215
pmcid: 10285541
doi: 10.3389/fphar.2023.1194719
Tolcher A, Hamilton E, Coleman RL. The evolving landscape of antibody-drug conjugates in gynecologic cancers. Cancer Treat Rev. 2023:102546.
Kobori T. New insights into immunotherapy for gynecological Cancer. J Clin Med. 2022:11.
Zhang C, Sheng Y, Sun X, Wang Y. New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions. Cancer Metastasis Rev. 2023:1–35.
Kurnit KC, Fleming GF, Lengyel E. Updates and new options in advanced epithelial ovarian cancer treatment. Obstet Gynecol. 2021;137:108.
pubmed: 33278287
doi: 10.1097/AOG.0000000000004173
Rai AK, Borah P, Kataki AC. Molecular profiling of Gynaecological Cancer and breast Cancer. In: Fundamentals in Gynaecologic malignancy. Springer; 2023. p. 9–24.
Johnson AM, Teoh D, Jewett P, Darst BF, Mattson J, Hoffmann C, et al. Genetic variants associated with post-traumatic stress symptoms in patients with gynecologic cancer. Gynecol Oncol. 2023;170:102–7.
pubmed: 36681010
doi: 10.1016/j.ygyno.2023.01.006
Beg A, Parveen R, Fouad H, Yahia ME, Hassanein AS. Role of different non-coding RNAs as ovarian cancer biomarkers. J Ovar Res. 2022;15:72.
doi: 10.1186/s13048-022-01002-3
Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen L-L, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24:430–47.
pubmed: 36596869
doi: 10.1038/s41580-022-00566-8
Yan H, Bu P. Non-coding RNA in cancer. Essays Biochem. 2021;65:625–39.
pubmed: 33860799
pmcid: 8564738
doi: 10.1042/EBC20200032
Ghafouri-Fard S, Esmaeili M, Taheri M. H19 lncRNA: roles in tumorigenesis. Biomed Pharmacother. 2020;123:109774.
pubmed: 31855739
doi: 10.1016/j.biopha.2019.109774
Yang J, Qi M, Fei X, Wang X, Wang K. LncRNA H19: A novel oncogene in multiple cancers. Int J Biol Sci. 2021;17:3188.
pubmed: 34421359
pmcid: 8375239
doi: 10.7150/ijbs.62573
Naz F, Tariq I, Ali S, Somaida A, Preis E, Bakowsky U. The role of long non-coding RNAs (lncRNAs) in female oriented cancers. Cancers. 2021;13:6102.
pubmed: 34885213
pmcid: 8656502
doi: 10.3390/cancers13236102
Xin W, Wang Y, Hua K, Liu S. The role of long noncoding RNA H19 in gynecological pathologies: insights into gene regulation and immune modulation (review). Int J Mol Med. 2023;52
Zhang L, Zhou Y, Huang T, Cheng AS, Yu J, Kang W, et al. The interplay of LncRNA-H19 and its binding partners in physiological process and gastric carcinogenesis. Int J Mol Sci. 2017;18:450.
pubmed: 28230721
pmcid: 5343984
doi: 10.3390/ijms18020450
Alipoor B, Parvar SN, Sabati Z, Ghaedi H, Ghasemi H. An updated review of the H19 lncRNA in human cancer: molecular mechanism and diagnostic and therapeutic importance. Mol Biol Rep. 2020;47:6357–74.
pubmed: 32743775
doi: 10.1007/s11033-020-05695-x
Monnier P, Martinet C, Pontis J, Stancheva I, Ait-Si-Ali S, Dandolo L. H19 lncRNA controls gene expression of the imprinted gene network by recruiting MBD1. Proc Natl Acad Sci. 2013;110:20693–8.
pubmed: 24297921
pmcid: 3870736
doi: 10.1073/pnas.1310201110
Imig J, Brunschweiger A, Brümmer A, Guennewig B, Mittal N, Kishore S, et al. miR-CLIP capture of a miRNA targetome uncovers a lincRNA H19-miR-106a interaction. Nat Chem Biol. 2015;11:107–14.
pubmed: 25531890
doi: 10.1038/nchembio.1713
Wang C, Plusquin M, Ghantous A, Herceg Z, Alfano R, Cox B, et al. DNA methylation of insulin-like growth factor 2 and H19 cluster in cord blood and prenatal air pollution exposure to fine particulate matter. Environ Health. 2020;19:1–12.
pubmed: 31898503
pmcid: 6941275
doi: 10.1186/s12940-019-0557-4
Zhong J, Tu X, Kong Y, Guo L, Li B, Zhong W, et al. LncRNA H19 promotes odontoblastic differentiation of human dental pulp stem cells by regulating miR-140-5p and BMP-2/FGF9. Stem Cell Res Ther. 2020;11:202.
pubmed: 32460893
pmcid: 7251819
doi: 10.1186/s13287-020-01698-4
Zeng L, Sun S, Han D, Liu Y, Liu H, Feng H, et al. Long non-coding RNA H19/SAHH axis epigenetically regulates odontogenic differentiation of human dental pulp stem cells. Cell Signal. 2018;52:65–73.
pubmed: 30165103
doi: 10.1016/j.cellsig.2018.08.015
Zeng H, He D, Xie H, Zhao Y, Peng Z, Deng H, et al. H19 regulates angiogenic capacity of extravillous trophoblasts by H19/miR-106a-5p/VEGFA axis. Arch Gynecol Obstet. 2020;301:671–9.
pubmed: 32107606
doi: 10.1007/s00404-020-05469-7
Huang Y, Zheng Y, Jia L, Li W. Long noncoding RNA H19 promotes osteoblast differentiation via TGF-β1/Smad3/HDAC signaling pathway by deriving miR-675. Stem Cells. 2015;33:3481–92.
pubmed: 26417995
doi: 10.1002/stem.2225
Liang W-C, Fu W-M, Wang Y-B, Sun Y-X, Xu L-L, Wong C-W, et al. H19 activates Wnt signaling and promotes osteoblast differentiation by functioning as a competing endogenous RNA. Sci Rep. 2016;6:1–11.
Lanzillotti C, De Mattei M, Mazziotta C, Taraballi F, Rotondo JC, Tognon M, et al. Long non-coding RNAs and microRNAs interplay in osteogenic differentiation of mesenchymal stem cells. Front Cell Dev Biol. 2021;9:646032.
pubmed: 33898434
pmcid: 8063120
doi: 10.3389/fcell.2021.646032
Zhong L, Liu P, Fan J, Luo Y. Long non-coding RNA H19: physiological functions and involvements in central nervous system disorders. Neurochem Int. 2021;148:105072.
pubmed: 34058282
doi: 10.1016/j.neuint.2021.105072
Chen S, Liu D, Zhou Z, Qin S. Role of long non-coding RNA H19 in the development of osteoporosis. Mol Med. 2021;27:1–10.
doi: 10.1186/s10020-021-00386-0
Su W, Huo Q, Wu H, Wang L, Ding X, Liang L, et al. The function of LncRNA-H19 in cardiac hypertrophy. Cell Biosci. 2021;11:1–11.
doi: 10.1186/s13578-021-00668-4
Hashemi M, Moosavi MS, Abed HM, Dehghani M, Aalipour M, Heydari EA, et al. Long non-coding RNA (lncRNA) H19 in human cancer: from proliferation and metastasis to therapy. Pharmacol Res. 2022;184:106418.
pubmed: 36038043
doi: 10.1016/j.phrs.2022.106418
Shuman C, Kalish JM, Weksberg R. Beckwith-wiedemann syndrome. GeneReviews®[Internet]; 2023.
Tang F, Zhang S, Wang H, Xu S, Yang S, Zhu X, et al. lncRNA H19 Promotes Ox-LDL-Induced Dysfunction of Human Aortic Endothelial Cells through the miR-152/VEGFA Axis. J Healthcare Eng. 2022, 2022;
Fan Z, Liu S, Zhou H. LncRNA H19 regulates proliferation, apoptosis and ECM degradation of aortic smooth muscle cells via miR-1-3p/ADAM10 axis in thoracic aortic aneurysm. Biochem Genet. 2022;60:790–806.
pubmed: 34478010
doi: 10.1007/s10528-021-10118-y
Heydari R, Fayazzadeh S, Shahrokh S, Shekari F, Farsad F, Meyfour A. Plasma extracellular vesicle LncRNA H19 as a potential diagnostic biomarker for inflammatory bowel diseases. Inflam Bowel Dis. 2023:izad219. https://doi.org/10.1093/ibd/izad219 .
Zhang X, Luo M, Zhang J, Guo B, Singh S, Lin X, et al. The role of lncRNA H19 in tumorigenesis and drug resistance of human cancers. Front Genet. 2022;13:1005522.
pubmed: 36246634
pmcid: 9555214
doi: 10.3389/fgene.2022.1005522
Yörüker EE, Keskin M, Kulle CB, Holdenrieder S, Gezer U. Diagnostic and prognostic value of circulating lncRNA H19 in gastric cancer. Biomed Rep. 2018;9:181–6.
pubmed: 30083318
pmcid: 6073100
Liu F-t. Pan H, Xia G-f, Qiu C, Zhu Z-m: prognostic and clinicopathological significance of long noncoding RNA H19 overexpression in human solid tumors: evidence from a meta-analysis. Oncotarget. 2016;7:83177.
pubmed: 27825121
pmcid: 5347760
doi: 10.18632/oncotarget.13076
Zhang L, Wang D, Yu P. LncRNA H19 regulates the expression of its target gene HOXA10 in endometrial carcinoma through competing with miR-612. Eur Rev Med Pharmacol Sci. 2018;22:4820–7.
pubmed: 30070313
Zhang K, Luo Z, Zhang Y, Zhang L, Wu L, Liu L, et al. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer. Cancer Biomark. 2016;17:187–94.
pubmed: 27540977
doi: 10.3233/CBM-160630
Tornesello ML, Faraonio R, Buonaguro L, Annunziata C, Starita N, Cerasuolo A, et al. The role of microRNAs, long non-coding RNAs, and circular RNAs in cervical cancer. Front Oncol. 2020;10:150.
pubmed: 32154165
pmcid: 7044410
doi: 10.3389/fonc.2020.00150
Liu S, Xin W, Tang X, Qiu J, Zhang Y, Hua K. LncRNA H19 overexpression in endometriosis and its utility as a novel biomarker for predicting recurrence. Reprod Sci. 2020;27:1687–97.
pubmed: 32468268
doi: 10.1007/s43032-019-00129-x
Sun H, Wang G, Peng Y, Zeng Y, Zhu QN, Li TL, et al. H19 lncRNA mediates 17β-estradiol-induced cell proliferation in MCF-7 breast cancer cells. Oncol Rep. 2015;33:3045–52.
pubmed: 25846769
doi: 10.3892/or.2015.3899
Si X, Zang R, Zhang E, Liu Y, Shi X, Zhang E, et al. LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. Oncotarget. 2016;7:81452–62.
pubmed: 27845892
pmcid: 5348405
doi: 10.18632/oncotarget.13263
Peng F, Li TT, Wang KL, Xiao GQ, Wang JH, Zhao HD, et al. H19/let-7/LIN28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance. Cell Death Dis. 2017;8:e2569.
pubmed: 28102845
pmcid: 5386357
doi: 10.1038/cddis.2016.438
Zhu QN, Wang G, Guo Y, Peng Y, Zhang R, Deng JL, et al. LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway. Oncotarget. 2017;8:91990–2003.
pubmed: 29190892
pmcid: 5696158
doi: 10.18632/oncotarget.21121
Zhou W, Ye XL, Xu J, Cao MG, Fang ZY, Li LY, et al. The lncRNA H19 mediates breast cancer cell plasticity during EMT and MET plasticity by differentially sponging miR-200b/c and let-7b. Sci Signal. 2017;10
Basak P, Chatterjee S, Bhat V, Su A, Jin H, Lee-Wing V, et al. Long non-coding RNA H19 acts as an estrogen receptor modulator that is required for endocrine therapy resistance in ER+ breast Cancer cells. Cell Physiol Biochem. 2018;51:1518–32.
pubmed: 30497079
doi: 10.1159/000495643
Gao H, Hao G, Sun Y, Li L, Wang Y. Long noncoding RNA H19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and EMT process. Onco Targets Ther. 2018;11:8001–12.
pubmed: 30519041
pmcid: 6235328
doi: 10.2147/OTT.S172379
Han J, Han B, Wu X, Hao J, Dong X, Shen Q, et al. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway. Toxicol Appl Pharmacol. 2018;359:55–61.
pubmed: 30244121
doi: 10.1016/j.taap.2018.09.018
Wang J, Xie S, Yang J, Xiong H, Jia Y, Zhou Y, et al. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy. J Hematol Oncol. 2019;12:81.
pubmed: 31340867
pmcid: 6657081
doi: 10.1186/s13045-019-0747-0
Sun Z, Zhang C, Wang T, Shi P, Tian X, Guo Y. Correlation between long non-coding RNAs (lncRNAs) H19 expression and trastuzumab resistance in breast cancer. J Cancer Res Ther. 2019;15:933–40.
pubmed: 31436255
doi: 10.4103/jcrt.JCRT_208_19
Wang Y, Wu Z, Li Y, Zheng Z, Yan J, Tian S, et al. Long non-coding RNA H19 promotes proliferation, migration and invasion and inhibits apoptosis of breast Cancer cells by targeting miR-491-5p/ZNF703 Axis. Cancer Manag Res. 2020;12:9247–58.
pubmed: 33061615
pmcid: 7532042
doi: 10.2147/CMAR.S246009
Yan L, Yang S, Yue CX, Wei XY, Peng W, Dong ZY, et al. Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells. Environ Toxicol. 2020;35:1015–28.
pubmed: 32420678
doi: 10.1002/tox.22938
Wang Y, Zhou P, Li P, Yang F, Gao XQ. Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1. Bioengineered. 2020;11:536–46.
pubmed: 32345117
pmcid: 8291873
doi: 10.1080/21655979.2020.1761512
Li Y, Ma H-Y, Hu X-W, Qu Y-Y, Wen X, Zhang Y, et al. LncRNA H19 promotes triple-negative breast cancer cells invasion and metastasis through the p53/TNFAIP8 pathway. Cancer Cell Int. 2020;20:200.
pubmed: 32514245
pmcid: 7257135
doi: 10.1186/s12935-020-01261-4
Sun H, Wang G, Cai J, Wei X, Zeng Y, Peng Y, et al. Long non-coding RNA H19 mediates N-acetyltransferase 1 gene methylation in the development of tamoxifen resistance in breast cancer. Exp Ther Med. 2022;23:12.
pubmed: 34815764
doi: 10.3892/etm.2021.10934
Chen J, Qin C, Zhou Y, Chen Y, Mao M, Yang J. Metformin may induce ferroptosis by inhibiting autophagy via lncRNA H19 in breast cancer. FEBS Open Bio. 2022;12:146–53.
pubmed: 34644456
doi: 10.1002/2211-5463.13314
Iempridee T. Long non-coding RNA H19 enhances cell proliferation and anchorage-independent growth of cervical cancer cell lines. Exp Biol Med (Maywood). 2017;242:184–93.
pubmed: 27633578
doi: 10.1177/1535370216670542
Peng L, Yuan XQ, Liu ZY, Li WL, Zhang CY, Zhang YQ, et al. High lncRNA H19 expression as prognostic indicator: data mining in female cancers and polling analysis in non-female cancers. Oncotarget. 2017;8:1655–67.
pubmed: 27926484
doi: 10.18632/oncotarget.13768
Ou L, Wang D, Zhang H, Yu Q, Hua F. Decreased expression of miR-138-5p by lncRNA H19 in cervical Cancer promotes tumor proliferation. Oncol Res. 2018;26:401–10.
pubmed: 28797320
pmcid: 7844697
doi: 10.3727/096504017X15017209042610
Huang MC, Chou YH, Shen HP, Ng SC, Lee YC, Sun YH, et al. The clinicopathological characteristic associations of long non-coding RNA gene H19 polymorphisms with uterine cervical cancer. J Cancer. 2019;10:6191–8.
pubmed: 31772651
pmcid: 6856740
doi: 10.7150/jca.36707
Zhu Z, Song L, He J, Sun Y, Liu X, Zou X. Ectopic expressed long non-coding RNA H19 contributes to malignant cell behavior of ovarian cancer. Int J Clin Exp Pathol. 2015;8:10082–91.
pubmed: 26617715
pmcid: 4637530
Zheng ZG, Xu H, Suo SS, Xu XL, Ni MW, Gu LH, et al. The essential role of H19 contributing to cisplatin resistance by regulating glutathione metabolism in high-grade serous ovarian Cancer. Sci Rep. 2016;6:26093.
pubmed: 27193186
pmcid: 4872133
doi: 10.1038/srep26093
Li J, Huang Y, Deng X, Luo M, Wang X, Hu H, et al. Long noncoding RNA H19 promotes transforming growth factor-β-induced epithelial-mesenchymal transition by acting as a competing endogenous RNA of miR-370-3p in ovarian cancer cells. Onco Targets Ther. 2018;11:427–40.
pubmed: 29403287
pmcid: 5783024
doi: 10.2147/OTT.S149908
Sajadpoor Z, Amini-Farsani Z, Teimori H, Shamsara M, Sangtarash MH, Ghasemi-Dehkordi P, et al. Valproic acid promotes apoptosis and cisplatin sensitivity through downregulation of H19 noncoding RNA in ovarian A2780 cells. Appl Biochem Biotechnol. 2018;185:1132–44.
pubmed: 29468525
doi: 10.1007/s12010-017-2684-0
Zheng X, Zhou Y, Chen W, Chen L, Lu J, He F, et al. Ginsenoside 20(S)-Rg3 prevents PKM2-targeting miR-324-5p from H19 sponging to antagonize the Warburg effect in ovarian Cancer cells. Cell Physiol Biochem. 2018;51:1340–53.
pubmed: 30481782
doi: 10.1159/000495552
Wu Y, Zhou Y, He J, Sun H, Jin Z. Long non-coding RNA H19 mediates ovarian cancer cell cisplatin-resistance and migration during EMT. Int J Clin Exp Pathol. 2019;12:2506–15.
pubmed: 31934077
pmcid: 6949588
Zhang H-B, Zeng Y, Li T-L, Wang G. Correlation between polymorphisms in IGF2/H19 gene locus and epithelial ovarian cancer risk in Chinese population. Genomics. 2020;112:2510–5.
pubmed: 32045670
doi: 10.1016/j.ygeno.2020.02.002
Wang Y, Gao WJ. Long non-coding RNA-H19 promotes ovarian cancer cell proliferation and migration via the microRNA-140/Wnt1 axis. Kaohsiung J Med Sci. 2021;37:768–75.
pubmed: 34002485
doi: 10.1002/kjm2.12393
Zhao L, Sun W, Zheng A, Zhang Y, Fang C, Zhang P. Ginsenoside Rg3 suppresses ovarian cancer cell proliferation and invasion by inhibiting the expression of lncRNA H19. Acta Biochim Pol. 2021;
Ghazal S, McKinnon B, Zhou J, Mueller M, Men Y, Yang L, et al. H19 lnc RNA alters stromal cell growth via IGF signaling in the endometrium of women with endometriosis. EMBO Mol Med. 2015;7:996–1003.
pubmed: 26089099
pmcid: 4551339
doi: 10.15252/emmm.201505245
Yan L, Zhou J, Gao Y, Ghazal S, Lu L, Bellone S, et al. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene. 2015;34:3076–84.
pubmed: 25088204
doi: 10.1038/onc.2014.236
Zhao L, Li Z, Chen W, Zhai W, Pan J, Pang H, et al. H19 promotes endometrial cancer progression by modulating epithelial-mesenchymal transition. Oncol Lett. 2017;13:363–9.
pubmed: 28123568
doi: 10.3892/ol.2016.5389
Liu Z, Liu L, Zhong Y, Cai M, Gao J, Tan C, et al. LncRNA H19 over-expression inhibited Th17 cell differentiation to relieve endometriosis through miR-342-3p/IER3 pathway. Cell Biosci. 2019;9:84.
pubmed: 31636893
pmcid: 6792244
doi: 10.1186/s13578-019-0346-3
Liu S, Qiu J, Tang X, Cui H, Zhang Q, Yang Q. LncRNA-H19 regulates cell proliferation and invasion of ectopic endometrium by targeting ITGB3 via modulating miR-124-3p. Exp Cell Res. 2019;381:215–22.
pubmed: 31085188
doi: 10.1016/j.yexcr.2019.05.010
Xu Z, Zhang L, Yu Q, Zhang Y, Yan L, Chen Z. The estrogen-regulated lncRNA H19/miR-216a-5p axis alters stromal cell invasion and migration via ACTA2 in endometriosis. Mol Hum Reprod. 2019;25:550–61.
pubmed: 31323679
doi: 10.1093/molehr/gaz040
Liu S, Xin W, Lu Q, Tang X, Wang F, Shao W, et al. Knockdown of lncRNA H19 suppresses endometriosis in vivo. Braz J Med Biol Res. 2021;54:e10117.
pubmed: 33656053
pmcid: 7917710
doi: 10.1590/1414-431x202010117
Liu S, Qiu J, Tang X, Li Q, Shao W. Estrogen regulates the expression and function of lncRNA-H19 in ectopic endometrium. Int J Women's Health. 2022;14:821.
doi: 10.2147/IJWH.S365943
Kamrani S, Amirchaghmaghi E, Ghaffari F, Shahhoseini M, Ghaedi K. Altered gene expression of VEGF, IGFs and H19 lncRNA and epigenetic profile of H19-DMR region in endometrial tissues of women with endometriosis. Reprod Health. 2022;19:1–9.
doi: 10.1186/s12978-022-01406-w
Szaflik T, Romanowicz H, Szyłło K, Kołaciński R, Michalska MM, Samulak D, et al. Analysis of long non-coding RNA (lncRNA) UCA1, MALAT1, TC0101441, and H19 expression in endometriosis. Int J Mol Sci. 2022;23:11583.
pubmed: 36232884
pmcid: 9570462
doi: 10.3390/ijms231911583
Shima H, Kida K, Adachi S, Yamada A, Sugae S, Narui K, et al. Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness. Breast Cancer Res Treat. 2018;170:507–16.
pubmed: 29693231
doi: 10.1007/s10549-018-4793-z
Sabnis AJ, Bivona TG. Principles of resistance to targeted cancer therapy: lessons from basic and translational cancer biology. Trends Mol Med. 2019;25:185–97.
pubmed: 30686761
pmcid: 6401263
doi: 10.1016/j.molmed.2018.12.009
Elias-Rizk T, El Hajj J, Segal-Bendirdjian E, Hilal G. The long non coding RNA H19 as a biomarker for breast cancer diagnosis in Lebanese women. Sci Rep. 2020;10:22228.
pubmed: 33335214
pmcid: 7747713
doi: 10.1038/s41598-020-79285-z
Özgür E, Ferhatoğlu F, Şen F, Saip P, Gezer U. Circulating lncRNA H19 may be a useful marker of response to neoadjuvant chemotherapy in breast cancer. Cancer Biomark. 2020;27:11–7.
pubmed: 31640083
doi: 10.3233/CBM-190085
Wang J, Sun J, Yang F. The role of long non-coding RNA H19 in breast cancer. Oncol Lett. 2020;19:7–16.
pubmed: 31897110
Tian X, Zuo X, Hou M, Li C, Teng Y. LncRNA-H19 regulates chemoresistance to carboplatin in epithelial ovarian cancer through microRNA-29b-3p and STAT3. J Cancer. 2021;12:5712.
pubmed: 34475985
pmcid: 8408112
doi: 10.7150/jca.58979
Zeng Y, Li T-L, Zhang H-B, Deng J-L, Zhang R, Sun H, et al. Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer. Pharmacogenomics. 2019;20:179–88.
pubmed: 30672383
doi: 10.2217/pgs-2018-0153
Zhao Y, Yin B, Xia B. Expression and clinical significance of long non-coding ribonucleic acid LOC554202 and H19 in serum of cervical Cancer. Indian J Pharm Sci. 2022:247–52.